The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved.
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
Wegovy and Ozempic. But for those with an aversion for needles, that’s a small price to pay. How it started In 2014, Novo Nordisk introduced the first GLP-1 agonist for weight loss, Saxenda ...
What if treating obesity could be as easy as popping an effective pill?
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback